NCT01003405WithdrawnPhase 3
A Open-label, Long-term Extension Study of KUC-7483 in Patients With Overactive Bladder
Kissei Pharmaceutical Co., Ltd.1 site in 1 country100 target enrollmentStarted: October 28, 2009Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Withdrawn
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- The long-term safety of KUC-7483 for the treatment of overactive bladder.
Study Overview
Brief Summary
To investigate the long-term safety, efficacy and pharmacokinetics of KUC-7483 in patients with overactive bladder.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 20 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients who have successfully completed the Phase III double-blind study.
Exclusion Criteria
- •Patients with serious adverse events or clinically significant adverse events in the Phase III double-blind study.
Arms & Interventions
KUC-7483
Experimental
Intervention: KUC-7483 (Drug)
Outcomes
Primary Outcomes
The long-term safety of KUC-7483 for the treatment of overactive bladder.
Time Frame: 52 weeks
Secondary Outcomes
- The long-term efficacy of KUC-7483 for the treatment of overactive bladder.(52 weeks)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Safety, Tolerability and Pharmacokinetics of KUC 7483 CL Tablets in Healthy Male VolunteersHealthyNCT02259933Boehringer Ingelheim35
Completed
Phase 3
An Open-label, Non-controlled Study of KHK4827 in Subjects With PsoriasisPsoriasisNCT01782937Kyowa Kirin Co., Ltd.30
Completed
Phase 3
Study of Pitavastatin in Elderly Patients With Primary Hypercholesterolemia or Combined DyslipidemiaDyslipidemiasHypercholesterolemiaNCT00330876Kowa Research Europe545
Completed
Phase 3
A Phase III Long Term Study of K-877 Extended Release TabletDyslipidemiasNCT04716595Kowa Company, Ltd.121
Completed
Phase 3
A Long-term Trial of OPC-34712 in Patients With SchizophreniaSchizophreniaNCT01456897Otsuka Pharmaceutical Co., Ltd.282